Get the Stockscreener App
99.67
1.96%
-1.99
After Hours:
99.67
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $99.67, with a volume of 9.24M.
It is down -1.96% in the last 24 hours and up +12.74% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$101.66
Open:
$100.52
24h Volume:
9.24M
Relative Volume:
0.68
Market Cap:
$173.61B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
32.22
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
+12.04%
1M Performance:
+12.74%
6M Performance:
-17.44%
1Y Performance:
-19.89%
1-Day Range:
$99.34
$101.83
1-Week Range:
$87.64
$102.46
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
99.67 | 177.07B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
314.58 | 122.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.35 | 106.61B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
43.19 | 65.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.55 | 48.94B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories - Yahoo Finance
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Lobbying Update: $1,150,000 of ABBOTT LABORATORIES lobbying was just disclosed - Quiver Quantitative
Abbott Laboratories stock trades steadily as diagnostics and medical devices underpin earnings momen - Ad-hoc-news.de
Craneware, Abbott Probe Separate Health Data Theft Incidents - BankInfoSecurity
Abbott Laboratories (NYSE:ABT) Faces A Major Medical Device Growth Test - Kalkine Media
ShinyHunters hit medial giant Abbott, disrupting cancer drug research and more - Yahoo Tech
Abbott Investigating Cyberattack Claims From Two Threat Actors - The HIPAA Journal
Healthcare giant Abbott probes two cyber incidents amid extortion claims - Malwarebytes
Abbott Laboratories investigates 2 separate cyber incidents - SC Media
Fairlife dairy cyberattack, ACR Stealer surge, Abbott Labs incidents - LinkedIn
Benchmark reiterates Buy on Abbott Labs stock, cites guidance raise - Investing.com
Abbott Laboratories stock trades steady as diagnostics and medical devices support growth - Ad-hoc-news.de
Cybersecurity News: Fairlife dairy cyberattack, ACR Stealer surge, Abbott Labs incidents - CISO Series
Abbott Laboratories Cybersecurity Breach Analysis: ShinyHunters Attack on Exact Sciences Systems and ShadowByt3$ LabCentral Portal Incident - Rescana
Abbott Investigates Two Separate Cyber Incidents, Says No Operations Affected - Insurance Journal
Abbott Laboratories stock holds firm as diagnostics and medical devices support earnings - ad-hoc-news.de
Medical giant Abbott investigates two cyber incidents as ShinyHunters claims breach - Cybernews
This Dividend ETF Yields 3.2% and Is Beating the Nasdaq-100 This Year - The Motley Fool
Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative - simplywall.st
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Abbott Laboratories (ABT) - The Globe and Mail
Abbott Stock: Bear Trap Over, With Richer Return Prospects (NYSE:ABT) - Seeking Alpha
Abbott Just Showed Its Growth Engine Has More Than One Cylinder - Trefis
Abbott investigates two separate cyber incidents, says no operations affected By Reuters - Investing.com
Abbott investigates two cyber intrusions targeting cancer diagnostics and LabCentral portal - Межа. Новини України.
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Keysight Invalidates IRS Rule On GILTI, Abbott Says - Law360
US companies face rise in cyber attacks - Reuters
Bernstein Adjusts Price Target on Abbott Laboratories to $117 From $110, Maintains Outperform Rating - Moomoo
Abbott probes two cyber incidents amid extortion claims - BleepingComputer
Abbott discloses cyberattack on cancer diagnostics business - MedTech Dive
ABT Reiterated by Piper Sandler -- Price Target Raised to $118 - GuruFocus
Can Abbott Laboratories (NYSE:ABT) Extend Its Dividend Strength? - Kalkine Media
Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance - TIKR.com
Abbott Laboratories Stock (ABT) Moved Up by 3.03% on Jul 17: Drivers Behind the Movement - TradingKey
ABT Q2 Earnings Call Flags Stronger Second-Half Setup - The Globe and Mail
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results - Benzinga
Benchmark reiterates Buy on Abbott Labs stock, keeps $120 target - Investing.com
Piper Sandler Adjusts Price Target on Abbott Laboratories to $118 From $115, Maintains Overweight Rating - Moomoo
Can Abbott Stock Deliver on Its Second-Half Growth Promise? - Trefis
Abbott Laboratories stock could rise 40%+ by 20... - Pluang
JPMorgan Adjusts Price Target on Abbott Laboratories to $120 From $110, Maintains Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $112, Maintains Outperform Rating - marketscreener.com
Abbott Laboratories: Pick Up This Dividend King Deal Now - Seeking Alpha
Raising Dividends for 54 Consecutive Years to Reward Shareholders, Abbott Laboratories’ Diversified Layout Consolidates Its Growth Foundation - NAI500
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street - Investing.com
What Helped Abbott Laboratories (NYSE:ABT) Raise Full-Year Outlook? - Kalkine Media
Abbott Laboratories (ABT) Could Be 15% Undervalued On Raised 2026 Earnings Outlook - simplywall.st
Why Abbott Stock Jumped Today - The Motley Fool
Abbott Laboratories Earnings Call Signals Broad-Based Momentum - TipRanks
ABT: Abbott Laboratories Exceeds Revenue and EPS Expectations, R - GuruFocus
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):